CWI India

CWI India appears to be a small India-based healthcare/regenerative medicine company focused on biologic medicine and commercialization or distribution partnerships rather than a broad in-house drug pipeline. Public evidence links the company to Organicell through a February 9, 2021 product testing and distribution agreement to study and potentially distribute Zofin in India for moderate to severe COVID-19 patients. Archived website content also describes partnerships with Organicell and Mayo Clinic and positions CWI India around regenerative medicine and biologic medicine. However, there is limited high-quality public disclosure about its corporate structure, management, locations, financing, or any independently developed assets, so many company attributes remain unverified.